Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Teva Pharma Industries Ltd ADR(TEVA)
Top performer 
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for TEVA
11/13/2026: TEVA (5-star) is a STRONG-BUY. BUY for 69 days. Simulated Profits (23.13%). Updated daily EoD!
Teva Pharma Industries Ltd is a global pharmaceutical leader that balances a vast generic medicine portfolio with a growing specialty drugs business. The company is currently executing a 'Pivot to Growth' strategy, emphasizing high-margin specialty products like AUSTEDO and AJOVY while working to reduce its historical debt burden. Its main strengths include unmatched manufacturing scale and a significant presence in global healthcare markets. Primary risks center on intense generic price competition and the management of long-term debt and legal liabilities. The stock may best suit value-oriented investors who monitor progress in debt reduction and the expansion of the specialty drug pipeline.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Growth investors may find interest in the potential of the specialty pipeline, though the base generic business remains slow-growth. |
| Momentum investor | Mixed fit | Momentum appeal is conditional on sustained positive price trends and execution of the growth strategy. |
| Value investor | Strong fit | The stock's valuation often reflects the risks associated with its debt profile, potentially offering a value proposition if deleveraging succeeds. |
| Dividend investor | Weak fit | Teva does not currently pay a dividend, making it unsuitable for income-focused investors. |
| Low-risk investor | Weak fit | Historical legal volatility and debt management challenges present a risk profile higher than typical low-risk investments. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock has experienced significant price swings driven by legal news and earnings surprises. |
| Valuation risk | Medium | Valuation depends heavily on the company's ability to maintain margins while reducing debt. |
| Competition risk (Generic Pricing) | High | Extreme commoditization in the generics market can erode profitability rapidly. |
| Business quality | Medium | While the manufacturing franchise is strong, historical debt and litigation impacts affect the overall business quality rating. |
| Dividend income | Low / none | The company has suspended dividends to focus on its balance sheet. |
| Execution risk | Medium / high | Success depends on the effective execution of the specialty pipeline and integration of biosimilars. |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 51.07B USD | Price to earnings Ratio 101.79 | 1Y Target Price 49.44 |
Price to earnings Ratio 101.79 | 1Y Target Price 49.44 | ||
Volume (30-day avg) 7.2M shares | Beta 0.84 | 52 Weeks Range 24.01 - 44.57 | Updated Date 11/13/2026 |
52 Weeks Range 24.01 - 44.57 | Updated Date 11/13/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.43 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Drug Manufacturers - Specialty & Generic
- BUY participation
- 66.7%
- Active BUY / eligible
- 8 / 12
- 30-Day BUY Count Change
- +3
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior
Hockey-Stick Growth
The stock demonstrates a Hockey-Stick Growth price path pattern.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 116.27% | Avg. Invested days 73 | Today’s Advisory Strong Buy |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 11/13/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Generics | Standardized copies of branded drugs sold globally. | The reliable core of the business that generates scale but faces constant price pressure. |
| Specialty Medicines | High-margin drugs like AUSTEDO and AJOVY. | The primary engine for future profit margin expansion. |
| Geography (Global) | Sales across North America, Europe, and International markets. | Geographic diversification helps buffer against regional pricing and regulatory risks. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-11-03 | When Before Market | Estimate 0.7 | Actual 0.83 |
Profitability
Profit Margin 2.94% | Operating Margin (TTM) 19.85% |
Management Effectiveness
Return on Assets (TTM) 5.35% | Return on Equity (TTM) 6.65% |
Valuation
Trailing PE 101.79 | Forward PE 12.55 | Enterprise Value 57.89B | Price to Sales(TTM) 2.96 |
Enterprise Value 57.89B | Price to Sales(TTM) 2.96 | ||
Enterprise Value to Revenue 3.35 | Enterprise Value to EBITDA 18.43 | Shares Outstanding 1.17B | Shares Floating 1.09B |
Shares Outstanding 1.17B | Shares Floating 1.09B | ||
Percent Insiders 0.48 | Percent Institutions 53.28 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.